Raymond R. Mandra

Of Counsel, New York

Since joining Fitzpatrick in 1989 Ray has concentrated in the areas of patent counseling, contentious proceedings before the United States Patent and Trademark Office, application writing, prosecution, litigation, licensing and due diligence primarily involving the chemical, food, pharmaceutical and biotechnological sciences. He chairs the firm’s Biotechnology Practice Group.

Ray has also prepared and provided counsel on numerous chemical, pharmaceutical and food related patent applications and patents for a number of clients and has extensive experience in the prosecution of both U.S. patent applications and international patent applications under the Patent Cooperation Treaty. He has also been substantially involved in various patent litigations, reexaminations, interferences and reissues and was also lead counsel in a number of inter-partes reviews.

Prior to joining Fitzpatrick, Ray worked for nine years as a chemist for the General Foods Corporation. His technological background has been instrumental in facilitating his quick understanding of the technology that is important to his clients.

Case Highlight
Ray Mandra led a team of Fitzpatrick attorneys that handled the patent due diligence for Valeant Pharmaceutical's $11 billion dollar acquisition of Salix Pharmaceutical. His strong technical background coupled with over 27 years of experience in both patent prosecution and litigation matters allowed Ray to quickly understand the patent issues associated with the complex technology being acquired and provide the client with the necessary counsel to assist in consummating the purchase.
What Others Say
  • “He is clear, concise, and very focused on providing the best service to his client” (2013 ILO Client Choice Individual Award for IP in the US)
  • “...Ray is a key member of the Fitzpatrick team that we count on” (2013 ILO Client Choice Individual Award for IP in the US)
  • “There is no one I trust more than Ray Mandra to prosecute our patent applications, coordinate IP diligence and assist me with IP strategy” (2012 ILO Client Choice Individual Award for IP in the US)
  • “He is always pleasant to do business with, even when faced with a request to do a significant amount of work in a very short period of time – we have never been told that something is impossible” (2012 ILO Client Choice Individual Award for IP in the US)
  • “He very quickly grasped the relevant technology, satisfying the expectations of our technical colleagues who are notoriously difficult to impress” (2012 ILO Client Choice Individual Award for IP in the US)
  • “outstanding”and “the best at pharmaceutical prosecution I have seen in my nearly 20 years in the industry” (Legal 500 2011)
Events / Publications
News & Press